ADELAIDE, Australia / RankWire.AI / – Researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have pinpointed a new molecular switch that influences the progression of highly aggressive tumors. The discovery was published in EMBO Molecular Medicine, and offers a promising new strategy to combat triple-negative breast cancer by restoring a vital regulatory molecule called miR-342. This breakthrough paves the way for new preventative strategies against secondary cancers in organs like the lungs and bones.
Although triple-negative breast cancer makes up 10% to 15% of the approximately 21,000 breast cancer cases diagnosed annually in Australia, it accounts for a disproportionate share of fatalities. This cancer subtype lacks estrogen, progesterone, and HER2 receptors, which makes standard hormone-targeted treatments ineffective. The lead researchers showed that a decline in miR-342 triggers overactivity of a cancer-promoting pathway called E2F, enabling dormant cancer cells to disseminate and develop into dangerous secondary tumors throughout the body.
Potential for Diagnostic Biomarker Testing to Pinpoint Patients Who Will Benefit Most
Pre-clinical experiments demonstrated that increasing miR-342 levels significantly reduced metastasis to distant organs. Researchers also found that palbociclib, a well-established CDK4/6 inhibitor used for hormone receptor-positive breast cancers, markedly suppressed metastatic tumor growth in models with low miR-342 expression. These results indicate that testing for miR-342 could help clinicians repurpose existing treatments for patients with high metastatic risk.
Associate Professor Philip Gregory, co-senior author from the Centre for Cancer Biology at Adelaide University, emphasized that metastasis prevention continues to be the foremost challenge in managing aggressive breast cancers. Gregory highlighted that since palbociclib targets the overactive E2F pathway, administering it after cancer cells have spread prevents microscopic deposits from expanding. This approach shifts focus from merely shrinking primary tumors to stopping early-stage secondary cancers from becoming life-threatening.
miR-342 as a Key Molecular Regulator for Cancer-Related Genes
The research team pointed out the biological heterogeneity of triple-negative breast cancer, which has historically hampered the development of universal targeted therapies. Identifying a specific vulnerability shared by a subgroup of patients offers an opportunity for tailored treatment approaches. As Australian scientists continue to explore this promising method, efforts are underway to validate these findings with patient-derived models prior to progressing into clinical trials.
The breakthrough has been welcomed by medical oncologists and cancer research organizations throughout Australia, given the critical need for expanded treatment options when primary therapies fall short. The team aims to collaborate with international clinical networks to fast-track biomarker screening processes. Confirming miR-342 testing could soon enable doctors to identify suitable candidates for early use of targeted CDK4/6 inhibitor treatments.